---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-031005"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-09-23T12:25:34+00:00"
generated_at: "2026-09-23T12:30:05.243011+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Moleculin secures Mexican patent for lung-targeted liposomal Annamycin through 2040

## Summary
- Mexican Patent Office granted Patent No. 436849 for lung-targeted liposomal Annamycin; expires Nov 23, 2040.
- Patent strengthens global IP for Annamycin, now in pivotal MIRACLE trial for relapsed/refractory AML.
- Issued 888,400 shares via ATM in Sept 2026 for $0.48M gross proceeds; shares outstanding now 20,385,780.
- Series I warrant exercise price reduced from $0.75 to $0.51 per share due to anti-dilution after ATM issuance.
- CEO Walter Klemp cites patent as reinforcing long-term commercial potential of Annamycin platform.

## SEC filing metadata
- accession: 0001437749-26-031005
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-09-23T12:25:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/0001437749-26-031005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926031005/mbrx20260922_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-031005
- JSON: https://secwatch.observer/filing/0001437749-26-031005.json
- Plain text: https://secwatch.observer/filing/0001437749-26-031005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.